Precigen (NASDAQ:PGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Precigen (NASDAQ:PGEN - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02, Zacks reports. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The business had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.30 million.

Precigen Trading Up 0.6 %

NASDAQ PGEN traded up $0.01 during trading on Friday, hitting $1.81. 2,345,706 shares of the company traded hands, compared to its average volume of 1,173,425. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17. The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.15. The company has a market capitalization of $532.22 million, a P/E ratio of -3.29 and a beta of 1.58.

Analysts Set New Price Targets

PGEN has been the subject of several recent research reports. JMP Securities reiterated a "market outperform" rating and set a $5.00 price objective on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Precigen in a report on Thursday. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.00.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.